A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

Neurology

Volumn 61, Issue 4, 2003, Pages 456-464

  Cudkowicz, Merit E ^a   Shefner, J M ^b   Schoenfeld, D A ^a   Brown Jr , R H ^a   Johnson, H ^a   Qureshi, M ^a   Jacobs, M ^a   Rothstein, J D ^c   Appel, S H ^d   Pascuzzi, R M ^e   Heiman Patterson, T D ^f   Donofrio, P D ^g   David, W S ^h   Russell, J A ⁱ   Tandan, R ^j   Pioro, E P ^k   Felice, K J ^l   Rosenfeld, J ^m   Mandler, R N ⁿ   Sachs, G M ^o   Bradley, W G ^p   Raynor, E M ^q   Baquis, G D ^r   Belsh, J M ^s   Novella, S ^t   Goldstein, J ^t   Hulihan, J ^u   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁱ LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^j UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^m Carolinas Medical System   (United States)

ⁿ GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^o RHODE ISLAND HOSPITAL   (United States)

^p UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^q BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^r BAYSTATE MEDICAL CENTER   (United States)

^s ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^t YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u Ortho McNeil Pharmaceutical Incorporated   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARTICLE; ASTHENIA; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; GRIP STRENGTH; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK ASSESSMENT; TASTE DISORDER; THOUGHT DISORDER; TREATMENT OUTCOME; VITAL CAPACITY; WEIGHT REDUCTION;

EID: 10744222650     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.61.4.456     Document Type: Article

References (29)

1. Rowland LP. Merritt's Textbook of Neurology, 9th ed. Philadelphia: Williams and Wilkins, 1995.
2. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in ALS. Neurology 1988;38:452-458.
3. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;236:1464-1468.
4. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow motor neuron toxicity. Proc Natl Acad Sci USA 1993;90:6591-6595.
5. Rothstein J, Van Kammen M, Levey A, Martin L, Kuncl R. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
6. Rothstein J. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. In: Serratrice G, Munsat T, eds. Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis. Philadelphia: Lippincott-Raven Publishers, 1995.
7. Rothstein J, Dykes-Hoberg M, Pardo C, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-686.
8. Sasaki S, Maruyama S, Yamane K, Sakuma H, Takeishi M. Ultrastructure of swollen proximal axons of anterior horn neurons in motor neuron disease. J Neurol Sci 1990;97:233-240.
9. Siklos L, Engelhardt J, Harati Y, Smith R, Joo F, Appel S. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 1996;39:203-219.
10. Wiedemann F, Winkler K, Kuznetsov A, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;156:65-72.
11. Masui Y, Mozai T, Kakehi K. Functional and morphometric study of the liver in motor neuron disease. J Neurol 1985;232:15-19.
12. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
13. Ferrante R, Browne S, Shinobu L, et al. Evidence of increased oxidative damage in both sporadic and familial ALS. J Neurochem 1997;69:2064-2074.
14. Carriedo S, Yin H, Lamberta R, Weiss J. In vitro kainate injury to large SMI-32+ spinal neurons is Ca2+ dependent. Neuroreport 1996;6:945-948.
15. Hugon J, Vallet J, Spencer P, Leboutet M, Barthe D. Kainic acid induces early and delayed degenerative neuronal changes in rat spinal cord. Neurosci Lett 1989;104:258-262.
16. Pascuzzi R. Presented at the 10th International Symposium on ALS and Motor Neuron Disease; November 2000; Arhus.
17. Skradski S, White H. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000;41(suppl 1):S45-S47.
18. Maragakis N, Jackson M, Ganel R, Rothstein J. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003;I338:107-110.
19. Brooks B. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis." J Neurol Sci 1994;124(suppl):96-107.
20. Andres P, Hedlund W, Finison L, Conlon T, Felmus M, Munsat T. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
21. Andres PL, Thibodeau LM, Finison LJ, Munsat TL. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 1987;5:125-141.
22. Miller R, Moore D, Young L, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-1388.
23. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
24. Cedarbaum J. The amyotrophic lateral sclerosis functional rating scale (ALSFRS). Arch Neurol 1996;53:141-147.
25. Schoenfeld D. Analysis of categorical data: logistic models. In: Miké V, Stanley K, eds. Statistics in Medical Research. New York: John Wiley and Sons, 1982:432-454.
26. Finkelstein D, Schoenfeld D. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18:1341-1354.
27. Miller R, Petajan J, Wilson W, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.
28. Rubin D. Inference and missing data. Biometrika 1976;63:581-590.
29. Smith-Swintosky V, Zhao B, Shank R, Plata-Salaman C. Topiramate promotes neurite outgrowth and recovery of function after nerve injury. Neuro Report 2001;12:1031-1034.